摘要
目的探讨食管癌患者血清中组织多肽特异抗原(TPS)的表达及临床意义。方法采用ELISA方法测定30例健康体检者,32例初治食管癌患者以及29例术后发现复发转移食管癌的血清中TPS水平,并观察其治疗前后变化。结果初治食管癌患者和术后复发转移食管癌的血清中TPS检测阳性率分别为31.2%和51.7%,均明显高于正常对照组的10.0%。初治食管癌不同临床分期间TPS水平变化无统计学意义(P>0.05),但治疗前后TPS水平变化差异有统计学意义(P<0.05)。术后复发转移食管癌的TPS水平较正常对照组高,差异有统计学意义(P<0.05),治疗有效者TPS水平显著下降(P<0.05)。结论动态监测血清TPS水平对食管癌术后复发转移和疗效评估有重要的临床应用价值。
Objective To value the clinical significance of serum TPS in patients with esophageal carcinoma. Methods Pretreatment TPS was measured by enzyme-linked immunoabsorbent assay in 30 healthy controls and 32 patients with primary esophageal carcinoma and 29 with recurrent or metastatic tumors after surgery, and observe the change of the TPS level before/after therapy. Results TPS positive rates in patients with primary tumor and with recurrent/metastasis tumor were 31.2 % and 51.7 %, respectively. The rates were both 10 % higher than that in controls. No significant difference were observed when TPS was categorized by clinical stage in patients with primary tumors（P 〉0.05）. Significant differences were observed between pre/posttherapy TPS（P 〈0.05）, TPS in patients with recurrent/metastasis tumors was higher than that in the controls（P 〈0.05）. TPS level decreased in the response patients（P 〈0.05）. Conclusions In the current study, TPS was found to be associated with tumor recurrent/metastasis and treatment response.
出处
《肿瘤研究与临床》
CAS
2005年第5期313-314,共2页
Cancer Research and Clinic
